Our Impact
With the launch of GBM AGILE, a new path has been uncovered—one that accelerates this pace of discovery from bench to bedside, and offers the greatest hope in the fight against cancer. Many important milestones have already been achieved, but there’s so much more on the horizon. Take a look and see how the generous support of our donors is making a difference, one dollar at a time.
“I was very impressed by everything I heard. I found the presented research to be of really high quality and very innovative. This is very refreshing, and, in my opinion, sets AIM-HI and NFCR apart in a very good way.” -Isidore Rigoutsos, Ph.D., Director, Center for Computational Medicine, Thomas Jefferson University
Isidore Rigoutsos, Ph.D.
Our Progress
Milestones We’ve Achieved Together
38 Trial Sites in the United States
1500 Patients Screened
30+ Global Sites Selected
6 Pharmaceutical Partners
In addition to the progress already achieved, the AGILE trial design will make an even greater impact. The AGILE trial approach will be used to combat other rare and deadly diseases, in the near future.
